Quick answers
- What is Auranofin used for?
- The FDA-approved label (Ridaura, Sebela Pharmaceuticals Inc., November 8, 2025) says: “RIDAURA (auranofin) is indicated in the management of adults with active classical or definite rheumatoid arthritis (ARA criteria) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs. RIDAURA should be added to a comprehensive baseline program, including non-drug therapies. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Auranofin have a boxed warning?
- Yes. The FDA label for Ridaura has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Auranofin?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Auranofin been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Auranofin?
- 2 companies list prescription products of Auranofin in the FDA NDC Directory, including Sebela Pharmaceuticals Inc. and Coral Way Pharma, LLC.
What Auranofin is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
RIDAURA (auranofin) is indicated in the management of adults with active classical or definite rheumatoid arthritis (ARA criteria) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs. RIDAURA should be added to a comprehensive baseline program, including non-drug therapies. …
— FDA label: Ridaura, Sebela Pharmaceuticals Inc., effective November 8, 2025. Read the full label on DailyMed →
The FDA has 2 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Read it on the full label →
2 of 2 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Capsule |
|---|---|
| Route | Oral |
| Prescription products | 2 in the FDA NDC Directory |
| Brand names | Ridaura |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| auranofin 3 mg capsule | Brand: Ridaura | $24.85 per capsule |
NADAC list of November 4, 2026; these prices took effect on December 17, 2025. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Sebela Pharmaceuticals Inc.1 product
- Coral Way Pharma, LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA018689 RIDAURA | Legacy | May 24, 1985 | 11, latest May 14, 2013 2013: Manufacturing (CMC) · 2002: Manufacturing (CMC) · 1999: Manufacturing (CMC) |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 197386, 213510 |
|---|---|
| SPL set ID of the quoted label | 43ba3de1-ab2e-06f6-e054-00144ff8d46c |
| FDA labels (SPL) | 2 |
| FDA applications | NDA018689 |
| Active ingredients (FDA) | AURANOFIN |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Ridaura, Sebela Pharmaceuticals Inc., effective November 8, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →